As of right now, stroke treatment focuses on established therapies like thrombolytic drugs [like tissue plasminogen activator (tPA)], and due to its properties, it is understandable why APC could be a potential treatment target (Dong et al., 2019; Lazic et al., 2019). This evidence concerns the gene PLAT and stroke disorder.